Ticker brief
REGN REGENERON PHARMACEUTICALS
Consumer, Non-cyclical · Biotechnology
last close
$654.27
1 day
+4.7%
14 days
+7.3%
mkt cap
$68.6B
signals 14d
33
authors 14d
25
Sentiment — last 14 days
daily mean sentiment, 2026-06-19 → 2026-07-03 · now +0.35 (−1 bearish … +1 bullish)
Who spoke25
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @bioinvestor24 | A | +1.35 | 4 | -0.00 |
| @Quantumup1 | C | -1.95 | 2 | +0.00 |
| @CrweWorld | C | · | 2 | +0.15 |
| @afortunetrading | C | +0.44 | 2 | +0.35 |
| @SixSigmaCapital | B | -0.48 | 2 | +0.30 |
| @Biotech2k1 | A | -0.03 | 2 | +0.40 |
| @VistaPResearch | C | · | 1 | +0.35 |
| @BioStocks | C | -0.39 | 1 | +0.45 |
| @OzmosiHealth | C | · | 1 | +0.45 |
| @FierceBiotech | A | -0.09 | 1 | -0.10 |
| @TheETFTracker | C | -0.29 | 1 | +0.00 |
| @cnfinancewatch | B | -1.61 | 1 | +0.25 |
| @InvestorIdeas | C | -0.30 | 1 | +0.25 |
| @semodough | C | -0.75 | 1 | +0.05 |
| @CNBC | C | -1.91 | 1 | +0.35 |
| @LiveSquawk | B | · | 1 | +0.50 |
| @EmmanuelInvest | C | -1.12 | 1 | +0.35 |
| @PowerLunch | C | -1.56 | 1 | +0.50 |
| @faststocknewss | C | -2.02 | 1 | +0.35 |
| @IngJuanPa7 | B | +2.30 | 1 | +0.35 |
| @RelentlesslyCu1 | C | +0.10 | 1 | +0.50 |
| @FiercePharma | B | +1.39 | 1 | +0.20 |
| @AmineTX | C | -2.25 | 1 | +0.35 |
| @Benzinga | C | -2.47 | 1 | +0.25 |
| @Arturraposo1R | B | -0.45 | 1 | +0.45 |
Recent signals30of 33 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-07-03 | @SixSigmaCapital | +0.15 | Reports named healthcare stocks have gained about 40% weighted in recent weeks. | — | tweet ↗ |
| 2026-07-03 | @Arturraposo1R | +0.45 | REGN looks good again with 30% upside to the 200WMA and appears to be value. | — | tweet ↗ |
| 2026-07-03 | @Biotech2k1 | +0.45 | Thinking about rotating biotech weighting into GILD and REGN. — Author is considering rotating into big-cap biotech names. | — | tweet ↗ |
| 2026-07-03 | @Biotech2k1 | +0.35 | Names GILD, REGN and ALNY as rotation plays to examine. | — | tweet ↗ |
| 2026-07-02 | @bioinvestor24 | +0.10 | Author says ABBV could make over $2B per year for years from the acquisition due to Dupixent LOE timing. | — | tweet ↗ |
| 2026-07-02 | @Quantumup1 | +0.00 | H.C. Wainwright reiterated ARWR Buy with $100 PT after cardiometabolic R&D webinar. | — | tweet ↗ |
| 2026-06-30 | @Benzinga | +0.25 | Eli Lilly, Amneal and Regeneron join FDA pilot to accelerate U.S. manufacturing readiness. | +4.9% | tweet ↗ |
| 2026-06-30 | @AmineTX | +0.35 | Eli Lilly and Regeneron join FDA pilot to accelerate US manufacturing readiness. | +4.9% | tweet ↗ |
| 2026-06-30 | @FiercePharma | +0.20 | FDA selects Lilly, Regeneron, Fujifilm and others for PreCheck pilot. | +4.9% | tweet ↗ |
| 2026-06-30 | @RelentlesslyCu1 | +0.50 | FDA named first seven companies for PreCheck Pilot, including Lilly and Regeneron. | +4.9% | tweet ↗ |
| 2026-06-29 | @CrweWorld | +0.30 | FDA selects named drug-manufacturing participants for PreCheck pilot program. | +3.6% | tweet ↗ |
| 2026-06-29 | @IngJuanPa7 | +0.35 | FDA selected LLY, REGN and others for PreCheck pilot to speed new pharma plant reviews. | +3.6% | tweet ↗ |
| 2026-06-29 | @faststocknewss | +0.35 | FDA selected named companies for PreCheck pilot to advance domestic drug manufacturing. | +3.6% | tweet ↗ |
| 2026-06-29 | @PowerLunch | +0.50 | LLY and REGN selected for FDA initiative to speed review of manufacturing facilities. | +3.6% | tweet ↗ |
| 2026-06-29 | @EmmanuelInvest | +0.35 | FDA selects Lilly and Regeneron for fast-track manufacturing review initiative. | +3.6% | tweet ↗ |
| 2026-06-29 | @LiveSquawk | +0.50 | LLY and REGN selected for FDA initiative to speed facility reviews. | +3.6% | tweet ↗ |
| 2026-06-29 | @CNBC | +0.35 | Eli Lilly and Regeneron selected for FDA initiative to speed manufacturing facility reviews. | +3.6% | tweet ↗ |
| 2026-06-28 | @SixSigmaCapital | +0.45 | REGN cited as net cash, PEG below 1, double-digit top line growth; worth a look. | +3.4% | tweet ↗ |
| 2026-06-27 | @semodough | +0.05 | Longer-term pipeline theme around transformative oral therapies in large autoimmune settings. | +3.4% | tweet ↗ |
| 2026-06-26 | @afortunetrading | +0.35 | Says software, cybersecurity and biotech names are looking good, but unsure if flow continues. | +3.4% | tweet ↗ |
| 2026-06-26 | @InvestorIdeas | +0.25 | Paid biotech news theme around vaccines, antibodies and therapeutics for 2026 Ebola outbreak. | +3.4% | tweet ↗ |
| 2026-06-26 | @afortunetrading | +0.35 | Lists relative-strength names and says IBB/XBI sector looks good. | +3.4% | tweet ↗ |
| 2026-06-26 | @cnfinancewatch | +0.25 | Three themes: memory pressure but intact AI demand, caution on small-cap AI, biotech M&A window. | +3.4% | tweet ↗ |
| 2026-06-25 | @CrweWorld | +0.00 | Regeneron to report Q2 2026 financial and operating results. | +5.5% | tweet ↗ |
| 2026-06-22 | @TheETFTracker | +0.00 | Rocket Lab entered NASDAQ 100 as 71st largest company in index. | +6.8% | tweet ↗ |
| 2026-06-22 | @FierceBiotech | -0.10 | AbbVie to buy Apogee for $10.9B, gaining eczema candidate that may threaten peers. | +6.8% | tweet ↗ |
| 2026-06-22 | @OzmosiHealth | +0.45 | Cemdisiran submissions accepted for FDA and EMA review. | +6.8% | tweet ↗ |
| 2026-06-22 | @Quantumup1 | +0.00 | H.C. Wainwright reiterated OCUL Buy and raised PT to $25 from $21. | +6.8% | tweet ↗ |
| 2026-06-22 | @BioStocks | +0.45 | REGN cemdisiran submissions accepted by FDA and EMA; FDA grants priority review with PDUFA Nov 2026. | +6.8% | tweet ↗ |
| 2026-06-21 | @VistaPResearch | +0.35 | Says Sanofi and Eupraxia belong on every immunology watchlist. | +7.3% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.